Haloperidol Oral Solution
 Haloperidol Tablets


|Haloperidol Oral Solution Haloperidol Tablets

Drugs search, click the first letter of a drug name:

| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home


Dosage Form: Oral solution


Haloperidol Description

Haloperidol is the first of the butyrophenone series of major tranquilizers. The chemical designation is 4-[4-(p-chlorophenyl)-4-hydroxy-piperidino]-4"-fluorobutyrophenone and it has the following structural formula:

Haloperidol ORAL SOLUTION USP (CONCENTRATE) contains 2 mg per mL Haloperidol (as the lactate).

Inactive ingredients: Lactic acid, methylparaben, propylparaben, propylene glycol, purified water, and sodium hydroxide to adjust pH.

Haloperidol - Clinical Pharmacology

The precise mechanism of action has not been clearly established.

Indications and Usage for Haloperidol

Haloperidol is indicated for use in the management of manifestations of psychotic disorders.

Haloperidol is indicated for the control of tics and vocal utterances of Tourette"s Disorder in children and adults.

Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation).

Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. This product should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics.


Haloperidol is contraindicated in severe toxic nervous system depression or comatose states from any cause and in individuals who are hypersensitive to this drug or have Parkinson"s disease.


Tardive Dyskinesia

Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalent estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

Both the risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome. (For further information about the description of tardive dyskinesia and its clinical detection, please refer to the section on ADVERSE REACTIONS).

Neuroleptic Malignant Syndrome (NMS) - a potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology.

The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

Hyperpyrexia and heat stroke, not associated with the above symptom complex, have also been reported with Haloperidol.

Usage in Pregnancy

Rodents given 2 to 20 times the usual maximum human dose of Haloperidol by oral or parenteral routes showed an increase in incidence of resorption, reduced fertility, delayed delivery and pup mortality. No teratogenic effect has been reported in rats, rabbits or dogs at dosages within this range, but cleft palate has been observed in mice given 15 times the usual maximum human dose. Cleft palate in mice appears to be a non-specific response to stress or nutritional imbalance as well as to a variety of drugs, and there is no evidence to relate this phenomenon to predictable human risk for most of these agents.

There are no well controlled studies with Haloperidol in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of Haloperidol along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to Haloperidol, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment.

Combined use of Haloperidol and Lithium

An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus Haloperidol. A causal relationship between these events and the concomitant administration of lithium and Haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.


A number of cases of bronchopneumonia, some fatal, have followed the use of antipsychotic drugs, including Haloperidol. It has been postulated that lethargy and decreased sensation of thirst due to central inhibition may lead to dehydration, hemoconcentration and reduced pulmonary ventilation. Therefore, if the above signs and symptoms appear, especially in the elderly, the physician should institute remedial therapy promptly.

Although not reported with Haloperidol, decreased serum cholesterol and/or cutaneous and ocular changes have been reported in patients receiving chemically-related drugs.

Haloperidol may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The ambulatory patient should be warned accordingly.

The use of alcohol with this drug should be avoided due to possible additive effects and hypotension.


Haloperidol should be administered cautiously to patients:

-with severe cardiovascular disorders, because of the possibility of transient hypotension and/or precipitation of anginal pain. Should hypotension occur and a vasopressor be required, epinephrine should not be used since Haloperidol may block its vasopressor activity and paradoxical further lowering of the blood pressure may occur. Instead, metaraminol, phenylephrine or norepinephrine should be used.

-receiving anticonvulsant medications, with a history of seizures or EEG abnormalities, because Haloperidol may lower the convulsive threshold. If indicated, adequate anticonvulsant therapy should be concomitantly maintained.

-with known allergies, or with a history of allergic reactions to drugs.

-receiving anticoagulants, since an isolated instance of interference occurred with the effects of one anticoagulant (phenindione).

If concomitant antiparkinson medication is required, it may have to be continued after Haloperidol is discontinued because of the difference in excretion rates. If both are discontinued simultaneously, extrapyramidal symptoms may occur. The physician should keep in mind the possible increase in intraocular pressure when anticholinergic drugs, including antiparkinson agents, are administered concomitantly with Haloperidol.

Concurrent administration of carbamazepine has been reported to produce a marked lowering of serum levels of Haloperidol.

As with other antipsychotic agents, it should be noted that Haloperidol may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.

When Haloperidol is used to control mania in cyclic disorders, there may be a rapid mood swing to depression.

Severe neurotoxicity (rigidity, inability to walk or talk) may occur in patients with thyrotoxicosis who are also receiving antipsychotic medication, including Haloperidol.

Carcinogenicity studies using oral Haloperidol were conducted in Wistar rats (dosed at up to 5 mg/kg daily for 24 months) and in Albino Swiss mice (dosed at up to 5 mg/kg daily for 18 months). In the rat study, survival was less than optimal in all dose groups, reducing the number of rats at risk for developing tumors. However, although a relatively greater number of rats survived to the end of the study in high dose male and female groups, these animals did not have a greater incidence of tumors than control animals. Therefore, although not optimal, this study does suggest the absence of a Haloperidol related increase in the incidence of neoplasia in rats at doses up to 20 times the usual daily human dose for chronic or resistant patients.

In female mice at 5 to 20 times the highest initial daily dose for chronic or resistant patients, there was a statistically significant increase in mammary gland neoplasia and total tumor incidence; at 20 times the same daily dose there was a statistically significant increase in pituitary gland neoplasia. In male mice, no statistically significant differences in incidences of total tumors or specific tumor types were noted.

Antipsychotic drugs elevate prolactin levels; the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time.

Adverse Reactions

CNS Effects

Extrapyramidal Reactions (EPS) - EPS during the administration of Haloperidol have been reported frequently, often during the first few days of treatment. In most patients, these reactions involved Parkinson-like symptoms which, when first observed, were usually mild to moderately severe and usually reversible. Other types of EPS (motor restlessness, dystonia, akathisia, hyperreflexia, opisthotonos, oculogyric crises) have been reported far less frequently, but can occur at relatively low doses and are often more severe. Generally the occurrence and severity of most EPS are dose related since they occur at relatively high doses and have been shown to disappear or become less severe when the dose is reduced. Administration of antiparkinson drugs such as benztropine mesylate or trihexyphenidyl hydrochloride may be required for control of such reactions. It should be noted that persistent EPS have been reported and that the drug may have to be discontinued in such cases.

Withdrawal Emergent Neurological Signs - Generally, patients receiving short term therapy experience no problems with abrupt discontinuation of antipsychotic drugs. However, some patients on maintenance treatment experience transient dyskinetic signs after abrupt withdrawal. In certain of these cases, the dyskinetic movements are indistinguishable from the syndrome described below under "Tardive Dyskinesia" except for duration. It is not known whether gradual withdrawal of antipsychotic drugs will reduce the rate of occurrence of withdrawal emergent neurological signs but until further evidence becomes available, it seems reasonable to gradually withdraw use of Haloperidol.

Tardive Dyskinesia - As with all antipsychotic agents Haloperidol has been associated with persistent dyskinesias. Tardive Dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients apparently irreversible. The syndrome is characterized by rhythmical involuntary movements of tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities and the trunk.

There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, this syndrome may be masked.

It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time the full syndrome may not develop.

Tardive Dystonia - Tardive dystonia, not associated with the above syndrome, has also been reported. Tardive dystonia is characterized by delayed onset of choreic or dystonic movements, is often persistent, and has the potential of becoming irreversible.

Other CNS Effects - Insomnia, restlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations, and catatonic-like behavioral states which may be responsive to drug withdrawal and/or treatment with anticholinergic drugs.

Body as a Whole

Neuroleptic malignant syndrome (NMS), hyperpyrexia and heat stroke have been reported with Haloperidol. (See WARNINGS for further information concerning NMS.)

Cardiovascular Effects

Tachycardia, Hypotension, Hypertension and ECG changes.

Hematologic Effects

Reports have appeared citing the occurrence of mild and usually transient leukopenia and leukocytosis, minimal decreases in red blood cell counts, anemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of Haloperidol, and then only in association with other medication.

Liver Effects

Impaired liver function and/or jaundice have been reported.

Dermatologic Reactions

Maculopapular and acneiform skin reactions and isolated cases of photosensitivity and loss of hair.

Endocrine Disorders

Lactation, breast engorgement, mastalgia, menstrual irregularities, gynecomastia, impotence, increased libido, hyperglycemia, hypoglycemia and hyponatremia.

Gastrointestinal Effects

Anorexia, constipation, diarrhea, hypersalivation, dyspepsia, nausea and vomiting.

Autonomic Reactions

Dry mouth, blurred vision, urinary retention, diaphoresis and priapism.

Respiratory Effects

Laryngospasm, bronchospasm and increased depth of respiration.

Special Senses

Cataracts, retinopathy and visual disturbances.


Cases of sudden and unexpected death have been reported in association with the administration of Haloperidol. The nature of the evidence makes it impossible to determine definitively what role, if any, Haloperidol played in the outcome of the reported cases.

The possibility that Haloperidol caused death cannot, of course, be excluded, but it is to be kept in mind that sudden and unexpected death may occur in psychotic patients when they go untreated or when they are treated with other antipsychotic drugs.


Manifestations - In general, the symptoms of overdosage would be an exaggeration of known pharmacologic effects and adverse reactions, the most prominent of which would be: 1) severe extrapyramidal reactions, 2) hypotension, or 3) sedation. The patient would appear comatose with respiratory depression and hypotension which could be severe enough to produce a shock-like state. The extrapyramidal reaction would be manifested by muscular weakness or rigidity and a generalized or localized tremor as demonstrated by the akinetic or agitans types respectively. With accidental overdosage, hypertension rather than hypotension occurred in a two-year old child.

Treatment - Gastric lavage or induction of emesis should be carried out immediately followed by administration of activated charcoal. Since there is no specific antidote, treatment is primarily supportive. A patent airway must be established by use of an oropharyngeal airway or endotracheal tube or, in prolonged cases of coma, by tracheostomy. Respiratory depression may be counteracted by artificial respiration and mechanical respirators. Hypotension and circulatory collapse may be counteracted by use of intravenous fluids, plasma, or concentrated albumin, and vasopressor agents such as metaraminol, phenylephrine and norepinephrine. Epinephrine should not be used. In case of severe extrapyramidal reactions, antiparkinson medication should be administered.

Haloperidol Dosage and Administration

There is considerable variation from patient to patient in the amount of medication required for treatment. As with all antipsychotic drugs, dosage should be individualized according to the needs and response of each patient. Dosage adjustments, either upward or downward, should be carried out as rapidly as practicable to achieve optimum therapeutic control.

To determine the initial dosage, consideration should be given to the patient"s age, severity of illness, previous response to other antipsychotic drugs, and any concomitant medication or disease state. Children, debilitated or geriatric patients, as well as those with a history of adverse reactions to antipsychotic drugs, may require less Haloperidol. The optimal response in such patients is usually obtained with more gradual dosage adjustments and at lower dosage levels, as recommended below.

Clinical experience suggests the following recommendations:

Oral Administration

Initial Dosage Range


0.5 mg to 2 mg
b.i.d. or t.i.d.
3 mg to 5 mg
b.i.d. or t.i.d.

To achieve prompt control, higher doses may be required in some cases.

Geriatric or Debilitated
0.5 mg to 2 mg
b.i.d. or t.i.d.
Chronic or Resistant
3 mg to 5 mg
b.i.d. or t.i.d.
Patients who remain severely disturbed or inadequately controlled may require dosage adjustment. Daily dosage up to 100 mg may be necessary in some cases to achieve an optimal response. Infrequently, Haloperidol has been used in doses above 100 mg for severely resistant patients; however, the limited clinical usage has not demonstrated the safety of prolonged administration of such doses.


The following recommendations apply to children between the ages of 3 and 12 years (weight range 15 to 40 kg). Haloperidol is not intended for children under 3 years old. Therapy should begin at the lowest dose possible (0.5 mg per day). If required, the dose should be increased by an increment of 0.5 mg at 5 to 7 day intervals until the desired therapeutic effect is obtained. (See chart below).

The total dose may be divided, to be given b.i.d. or t.i.d.

Psychotic Disorders 0.05 mg/kg/day to
0.15 mg/kg/day
Non-Psychotic Behavior Disorders and Tourette"s Disorder 0.05 mg/kg/day to
0.075 mg/kg/day
Severely disturbed psychotic children may require higher doses. In severely disturbed, non-psychotic children or in hyperactive children with accompanying conduct disorders, who have failed to respond to psychotherapy or medications other than antipsychotics it should be noted that since these behaviors may be short-lived, short-term administration of Haloperidol may suffice. There is no evidence establishing a maximum effective dosage. There is little evidence that behavior improvement is further enhanced in dosages beyond 6 mg per day.

Maintenance Dosage

Upon achieving a satisfactory therapeutic response, dosage should be gradually reduced to the lowest effective maintenance level.

Switchover Procedure (From Intramuscular Administration)

The oral form should supplant the injectable as soon as practicable. In the absence of bioavailability studies establishing bioequivalence between these two dosage forms the following guidelines for dosage are suggested. For an initial approximation of the total daily dose required, the parenteral dose administered in the preceding 24 hours may be used. Since this dose is only an initial estimate, it is recommended that careful monitoring of clinical signs and symptoms, including clinical efficacy, sedation, and adverse effects, be carried out periodically for the first several days following the initiation of switchover. In this way, dosage adjustments, either upward or downward, can be quickly accomplished. Depending on the patient"s clinical status, the first oral dose should be given within 12-24 hours following the last parenteral dose.

How is Haloperidol Supplied

Haloperidol ORAL SOLUTION USP (CONCENTRATE), 2 mg per mL (as the lactate) is a colorless, odorless, and tasteless solution available in bottles of 120 mL (NDC 0121-0581-04) with accompanying dropper calibrated at 1.0 mg, 1.5 mg, 2.0 mg, 3.0 mg, 4.0 mg and 5.0 mg and Unit Dose cups of 10 mg/5 mL (NDC 0121-0581-05) available as 10 Unit Dose cups per tray, 10 trays per case.

Store at controlled room temperature, 20°-25°C (68°-77°F). [See USP]

Dispense in tight, light-resistant container as described in the official compendium.


Haloperidol (Haloperidol)
Product Code 0121-0581 Dosage Form SOLUTION
Route Of Administration ORAL DEA Schedule
Name (Active Moiety) Type Strength
Haloperidol (Haloperidol) Active 2 MILLIGRAM  In 1 MILLILITER
Lactic Acid Inactive  
Methylparaben Inactive  
Propylparaben Inactive  
Propylene Glycol Inactive  
Purified Water Inactive  
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
# NDC Package Description Multilevel Packaging
1 0121-0581-04 120 MILLILITER In 1 BOTTLE None
2 0121-0581-05 100 CUP In 1 CASE contains a CUP, UNIT-DOSE
2 5 MILLILITER In 1 CUP, UNIT-DOSE This package is contained within the CASE (0121-0581-05)

Revised: 10/2006

Where can I get more information about Haloperidol Oral Solution Haloperidol Tablets ? We recommend to use www.Drugs.com

Typical mistypes for Haloperidol Oral Solution Haloperidol Tablets
galoperidol oral solution haloperidol tablets, baloperidol oral solution haloperidol tablets, naloperidol oral solution haloperidol tablets, jaloperidol oral solution haloperidol tablets, ualoperidol oral solution haloperidol tablets, yaloperidol oral solution haloperidol tablets, hzloperidol oral solution haloperidol tablets, hsloperidol oral solution haloperidol tablets, hwloperidol oral solution haloperidol tablets, hqloperidol oral solution haloperidol tablets, hakoperidol oral solution haloperidol tablets, hapoperidol oral solution haloperidol tablets, haooperidol oral solution haloperidol tablets, haliperidol oral solution haloperidol tablets, halkperidol oral solution haloperidol tablets, hallperidol oral solution haloperidol tablets, halpperidol oral solution haloperidol tablets, hal0peridol oral solution haloperidol tablets, hal9peridol oral solution haloperidol tablets, halooeridol oral solution haloperidol tablets, haloleridol oral solution haloperidol tablets, halo-eridol oral solution haloperidol tablets, halo0eridol oral solution haloperidol tablets, halopwridol oral solution haloperidol tablets, halopsridol oral solution haloperidol tablets, halopdridol oral solution haloperidol tablets, haloprridol oral solution haloperidol tablets, halop4ridol oral solution haloperidol tablets, halop3ridol oral solution haloperidol tablets, halopeeidol oral solution haloperidol tablets, halopedidol oral solution haloperidol tablets, halopefidol oral solution haloperidol tablets, halopetidol oral solution haloperidol tablets, halope5idol oral solution haloperidol tablets, halope4idol oral solution haloperidol tablets, haloperudol oral solution haloperidol tablets, haloperjdol oral solution haloperidol tablets, haloperkdol oral solution haloperidol tablets, haloperodol oral solution haloperidol tablets, haloper9dol oral solution haloperidol tablets, haloper8dol oral solution haloperidol tablets, haloperisol oral solution haloperidol tablets, haloperixol oral solution haloperidol tablets, halopericol oral solution haloperidol tablets, haloperifol oral solution haloperidol tablets, haloperirol oral solution haloperidol tablets, haloperieol oral solution haloperidol tablets, haloperidil oral solution haloperidol tablets, haloperidkl oral solution haloperidol tablets, haloperidll oral solution haloperidol tablets, haloperidpl oral solution haloperidol tablets, haloperid0l oral solution haloperidol tablets, haloperid9l oral solution haloperidol tablets, haloperidok oral solution haloperidol tablets, haloperidop oral solution haloperidol tablets, haloperidoo oral solution haloperidol tablets, haloperidol iral solution haloperidol tablets, haloperidol kral solution haloperidol tablets, haloperidol lral solution haloperidol tablets, haloperidol pral solution haloperidol tablets, haloperidol 0ral solution haloperidol tablets, haloperidol 9ral solution haloperidol tablets, haloperidol oeal solution haloperidol tablets, haloperidol odal solution haloperidol tablets, haloperidol ofal solution haloperidol tablets, haloperidol otal solution haloperidol tablets, haloperidol o5al solution haloperidol tablets, haloperidol o4al solution haloperidol tablets, haloperidol orzl solution haloperidol tablets, haloperidol orsl solution haloperidol tablets, haloperidol orwl solution haloperidol tablets, haloperidol orql solution haloperidol tablets, haloperidol orak solution haloperidol tablets, haloperidol orap solution haloperidol tablets, haloperidol orao solution haloperidol tablets, haloperidol oral aolution haloperidol tablets, haloperidol oral zolution haloperidol tablets, haloperidol oral xolution haloperidol tablets, haloperidol oral dolution haloperidol tablets, haloperidol oral eolution haloperidol tablets, haloperidol oral wolution haloperidol tablets, haloperidol oral silution haloperidol tablets, haloperidol oral sklution haloperidol tablets, haloperidol oral sllution haloperidol tablets, haloperidol oral splution haloperidol tablets, haloperidol oral s0lution haloperidol tablets, haloperidol oral s9lution haloperidol tablets, haloperidol oral sokution haloperidol tablets, haloperidol oral sopution haloperidol tablets, haloperidol oral sooution haloperidol tablets, haloperidol oral solytion haloperidol tablets, haloperidol oral solhtion haloperidol tablets, haloperidol oral soljtion haloperidol tablets, haloperidol oral solition haloperidol tablets, haloperidol oral sol8tion haloperidol tablets, haloperidol oral sol7tion haloperidol tablets, haloperidol oral solurion haloperidol tablets, haloperidol oral solufion haloperidol tablets, haloperidol oral solugion haloperidol tablets, haloperidol oral soluyion haloperidol tablets, haloperidol oral solu6ion haloperidol tablets, haloperidol oral solu5ion haloperidol tablets, haloperidol oral solutuon haloperidol tablets, haloperidol oral solutjon haloperidol tablets, haloperidol oral solutkon haloperidol tablets, haloperidol oral solutoon haloperidol tablets, haloperidol oral solut9on haloperidol tablets, haloperidol oral solut8on haloperidol tablets, haloperidol oral solutiin haloperidol tablets, haloperidol oral solutikn haloperidol tablets, haloperidol oral solutiln haloperidol tablets, haloperidol oral solutipn haloperidol tablets, haloperidol oral soluti0n haloperidol tablets, haloperidol oral soluti9n haloperidol tablets, haloperidol oral solutiob haloperidol tablets, haloperidol oral solutiom haloperidol tablets, haloperidol oral solutioj haloperidol tablets, haloperidol oral solutioh haloperidol tablets, haloperidol oral solution galoperidol tablets, haloperidol oral solution baloperidol tablets, haloperidol oral solution naloperidol tablets, haloperidol oral solution jaloperidol tablets, haloperidol oral solution ualoperidol tablets, haloperidol oral solution yaloperidol tablets, haloperidol oral solution hzloperidol tablets, haloperidol oral solution hsloperidol tablets, haloperidol oral solution hwloperidol tablets, haloperidol oral solution hqloperidol tablets, haloperidol oral solution hakoperidol tablets, haloperidol oral solution hapoperidol tablets, haloperidol oral solution haooperidol tablets, haloperidol oral solution haliperidol tablets, haloperidol oral solution halkperidol tablets, haloperidol oral solution hallperidol tablets, haloperidol oral solution halpperidol tablets, haloperidol oral solution hal0peridol tablets, haloperidol oral solution hal9peridol tablets, haloperidol oral solution halooeridol tablets, haloperidol oral solution haloleridol tablets, haloperidol oral solution halo-eridol tablets, haloperidol oral solution halo0eridol tablets, haloperidol oral solution halopwridol tablets, haloperidol oral solution halopsridol tablets, haloperidol oral solution halopdridol tablets, haloperidol oral solution haloprridol tablets, haloperidol oral solution halop4ridol tablets, haloperidol oral solution halop3ridol tablets, haloperidol oral solution halopeeidol tablets, haloperidol oral solution halopedidol tablets, haloperidol oral solution halopefidol tablets, haloperidol oral solution halopetidol tablets, haloperidol oral solution halope5idol tablets, haloperidol oral solution halope4idol tablets, haloperidol oral solution haloperudol tablets, haloperidol oral solution haloperjdol tablets, haloperidol oral solution haloperkdol tablets, haloperidol oral solution haloperodol tablets, haloperidol oral solution haloper9dol tablets, haloperidol oral solution haloper8dol tablets, haloperidol oral solution haloperisol tablets, haloperidol oral solution haloperixol tablets, haloperidol oral solution halopericol tablets, haloperidol oral solution haloperifol tablets, haloperidol oral solution haloperirol tablets, haloperidol oral solution haloperieol tablets, haloperidol oral solution haloperidil tablets, haloperidol oral solution haloperidkl tablets, haloperidol oral solution haloperidll tablets, haloperidol oral solution haloperidpl tablets, haloperidol oral solution haloperid0l tablets, haloperidol oral solution haloperid9l tablets, haloperidol oral solution haloperidok tablets, haloperidol oral solution haloperidop tablets, haloperidol oral solution haloperidoo tablets, haloperidol oral solution haloperidol rablets, haloperidol oral solution haloperidol fablets, haloperidol oral solution haloperidol gablets, haloperidol oral solution haloperidol yablets, haloperidol oral solution haloperidol 6ablets, haloperidol oral solution haloperidol 5ablets, haloperidol oral solution haloperidol tzblets, haloperidol oral solution haloperidol tsblets, haloperidol oral solution haloperidol twblets, haloperidol oral solution haloperidol tqblets, haloperidol oral solution haloperidol tavlets, haloperidol oral solution haloperidol tanlets, haloperidol oral solution haloperidol tahlets, haloperidol oral solution haloperidol taglets, haloperidol oral solution haloperidol tabkets, haloperidol oral solution haloperidol tabpets, haloperidol oral solution haloperidol taboets, haloperidol oral solution haloperidol tablwts, haloperidol oral solution haloperidol tablsts, haloperidol oral solution haloperidol tabldts, haloperidol oral solution haloperidol tablrts, haloperidol oral solution haloperidol tabl4ts, haloperidol oral solution haloperidol tabl3ts, haloperidol oral solution haloperidol tablers, haloperidol oral solution haloperidol tablefs, haloperidol oral solution haloperidol tablegs, haloperidol oral solution haloperidol tableys, haloperidol oral solution haloperidol table6s, haloperidol oral solution haloperidol table5s, haloperidol oral solution haloperidol tableta, haloperidol oral solution haloperidol tabletz, haloperidol oral solution haloperidol tabletx, haloperidol oral solution haloperidol tabletd, haloperidol oral solution haloperidol tablete, haloperidol oral solution haloperidol tabletw, aloperidol oral solution haloperidol tablets, hloperidol oral solution haloperidol tablets, haoperidol oral solution haloperidol tablets, halperidol oral solution haloperidol tablets, haloeridol oral solution haloperidol tablets, halopridol oral solution haloperidol tablets, halopeidol oral solution haloperidol tablets, haloperdol oral solution haloperidol tablets, haloperiol oral solution haloperidol tablets, haloperidl oral solution haloperidol tablets, haloperido oral solution haloperidol tablets, haloperidoloral solution haloperidol tablets, haloperidol ral solution haloperidol tablets, haloperidol oal solution haloperidol tablets, haloperidol orl solution haloperidol tablets, haloperidol ora solution haloperidol tablets, haloperidol oralsolution haloperidol tablets, haloperidol oral olution haloperidol tablets, haloperidol oral slution haloperidol tablets, haloperidol oral soution haloperidol tablets, haloperidol oral soltion haloperidol tablets, haloperidol oral soluion haloperidol tablets, haloperidol oral soluton haloperidol tablets, haloperidol oral solutin haloperidol tablets, haloperidol oral solutio haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution aloperidol tablets, haloperidol oral solution hloperidol tablets, haloperidol oral solution haoperidol tablets, haloperidol oral solution halperidol tablets, haloperidol oral solution haloeridol tablets, haloperidol oral solution halopridol tablets, haloperidol oral solution halopeidol tablets, haloperidol oral solution haloperdol tablets, haloperidol oral solution haloperiol tablets, haloperidol oral solution haloperidl tablets, haloperidol oral solution haloperido tablets, haloperidol oral solution haloperidoltablets, haloperidol oral solution haloperidol ablets, haloperidol oral solution haloperidol tblets, haloperidol oral solution haloperidol talets, haloperidol oral solution haloperidol tabets, haloperidol oral solution haloperidol tablts, haloperidol oral solution haloperidol tables, haloperidol oral solution haloperidol tablet, ahloperidol oral solution haloperidol tablets, hlaoperidol oral solution haloperidol tablets, haolperidol oral solution haloperidol tablets, halpoeridol oral solution haloperidol tablets, haloepridol oral solution haloperidol tablets, halopreidol oral solution haloperidol tablets, halopeirdol oral solution haloperidol tablets, haloperdiol oral solution haloperidol tablets, haloperiodl oral solution haloperidol tablets, haloperidlo oral solution haloperidol tablets, haloperido loral solution haloperidol tablets, haloperidolo ral solution haloperidol tablets, haloperidol roal solution haloperidol tablets, haloperidol oarl solution haloperidol tablets, haloperidol orla solution haloperidol tablets, haloperidol ora lsolution haloperidol tablets, haloperidol orals olution haloperidol tablets, haloperidol oral oslution haloperidol tablets, haloperidol oral sloution haloperidol tablets, haloperidol oral soultion haloperidol tablets, haloperidol oral soltuion haloperidol tablets, haloperidol oral soluiton haloperidol tablets, haloperidol oral solutoin haloperidol tablets, haloperidol oral solutino haloperidol tablets, haloperidol oral solutio n haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution h aloperidol tablets, haloperidol oral solution ahloperidol tablets, haloperidol oral solution hlaoperidol tablets, haloperidol oral solution haolperidol tablets, haloperidol oral solution halpoeridol tablets, haloperidol oral solution haloepridol tablets, haloperidol oral solution halopreidol tablets, haloperidol oral solution halopeirdol tablets, haloperidol oral solution haloperdiol tablets, haloperidol oral solution haloperiodl tablets, haloperidol oral solution haloperidlo tablets, haloperidol oral solution haloperido ltablets, haloperidol oral solution haloperidolt ablets, haloperidol oral solution haloperidol atblets, haloperidol oral solution haloperidol tbalets, haloperidol oral solution haloperidol talbets, haloperidol oral solution haloperidol tabelts, haloperidol oral solution haloperidol tabltes, haloperidol oral solution haloperidol tablest, hhaloperidol oral solution haloperidol tablets, haaloperidol oral solution haloperidol tablets, halloperidol oral solution haloperidol tablets, halooperidol oral solution haloperidol tablets, halopperidol oral solution haloperidol tablets, halopeeridol oral solution haloperidol tablets, haloperridol oral solution haloperidol tablets, haloperiidol oral solution haloperidol tablets, haloperiddol oral solution haloperidol tablets, haloperidool oral solution haloperidol tablets, haloperidoll oral solution haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol ooral solution haloperidol tablets, haloperidol orral solution haloperidol tablets, haloperidol oraal solution haloperidol tablets, haloperidol orall solution haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral ssolution haloperidol tablets, haloperidol oral soolution haloperidol tablets, haloperidol oral sollution haloperidol tablets, haloperidol oral soluution haloperidol tablets, haloperidol oral soluttion haloperidol tablets, haloperidol oral solutiion haloperidol tablets, haloperidol oral solutioon haloperidol tablets, haloperidol oral solutionn haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution hhaloperidol tablets, haloperidol oral solution haaloperidol tablets, haloperidol oral solution halloperidol tablets, haloperidol oral solution halooperidol tablets, haloperidol oral solution halopperidol tablets, haloperidol oral solution halopeeridol tablets, haloperidol oral solution haloperridol tablets, haloperidol oral solution haloperiidol tablets, haloperidol oral solution haloperiddol tablets, haloperidol oral solution haloperidool tablets, haloperidol oral solution haloperidoll tablets, haloperidol oral solution haloperidol tablets, haloperidol oral solution haloperidol ttablets, haloperidol oral solution haloperidol taablets, haloperidol oral solution haloperidol tabblets, haloperidol oral solution haloperidol tabllets, haloperidol oral solution haloperidol tableets, haloperidol oral solution haloperidol tabletts, haloperidol oral solution haloperidol tabletss, etc.

© Copyright by drug-information.ru 2001-2019. All rights reserved